Literature DB >> 33122828

Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.

Yuefeng Jia1, Xuemei Ding2, Lihua Zhou3, Li Zhang2, Xuecheng Yang4.   

Abstract

microRNAs (miRNAs) can be delivered to tumor cells where they exert their function via mesenchymal stem cells (MSCs)-derived exosomes. This study investigated exosomal transfer of miR-139-5p to bladder cancer cells and their role in the regulation of tumorigenesis. The dysregulation of polycomb repressor complex 1 (PRC1) in bladder cancer was characterized by RNA quantification, and its functional significance in bladder cancer cells was identified by loss-of-function experiments. We predicted the miR-139-5p that could play a role in regulating PRC1, which was further verified using dual-luciferase reporter gene assay. Next, we altered the expression of miR-139-5p and PRC1 in bladder cancer cells to identify their functions in cancer progression. Bladder cancer cells were co-cultured with exosomes isolated from human umbilical cord mesenchymal stem cells (hUCMSCs) over-expressing miR-139-5p. The intercellular transfer of miR-139-5p along with in vitro and in vivo functions was determined using gain- and loss-of-function approaches. Our results revealed that PRC1 levels were increased in bladder cancer tissues and cells, and silencing PRC1 appeared to impede the cell proliferation, migration, and invasion potentials. In addition, miR-139-5p was observed to be down-regulated in bladder cancer, which targeted PRC1 and reduced its expression, hereby resulting in ameliorated tumorigenic characteristics of bladder cancer cells in vitro. Furthermore, we noted that miR-139-5p from hUCMSCs-derived exosomes could be transferred into bladder cancer cells to down-regulate the PRC1 expression. Moreover, hUCMSCs-derived exosomal miR-139-5p conferred a suppressive role on bladder cancer development in vitro and in vivo. These data together supported the tumor-inhibiting role of MSCs-derived exosomal miR-139-5p in bladder cancer, highlighting a promising therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33122828     DOI: 10.1038/s41388-020-01486-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer.

Authors:  Wei Xu; Meng Hang; Chen-Ye Yuan; Fu-Lin Wu; Shu-Bo Chen; Kai Xue
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

2.  MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene.

Authors:  Hongbo Luo; Rui Yang; Chun Li; Yongqing Tong; Lingling Fan; Xiuheng Liu; Chuanrui Xu
Journal:  Tumour Biol       Date:  2017-07

3.  MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1.

Authors:  Qian Sun; Danhui Weng; Kezhen Li; Shuang Li; Xiangyang Bai; Can Fang; Danfeng Luo; Peng Wu; Gang Chen; Juncheng Wei
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

  3 in total
  22 in total

1.  Human umbilical cord mesenchymal stem cell-derived extracellular vesicles carrying miR-655-3p inhibit the development of esophageal cancer by regulating the expression of HIF-1α via a LMO4/HDAC2-dependent mechanism.

Authors:  Mingjiu Chen; Zhenkun Xia; Jie Deng
Journal:  Cell Biol Toxicol       Date:  2022-10-12       Impact factor: 6.819

Review 2.  Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications.

Authors:  Huali Ye; Xin Hu; Yang Wen; Chongqi Tu; Francis Hornicek; Zhenfeng Duan; Li Min
Journal:  J Nanobiotechnology       Date:  2022-09-05       Impact factor: 9.429

3.  Intravenously transplanted mesenchymal stromal cells: a new endocrine reservoir for cardioprotection.

Authors:  Anan Huang; Yue Liu; Xin Qi; Shang Chen; Haoyan Huang; Jun Zhang; Zhibo Han; Zhong-Chao Han; Zongjin Li
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

Review 4.  Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.

Authors:  Behnoush Sohrabi; Behnaz Dayeri; Elahe Zahedi; Shahrouz Khoshbakht; Najme Nezamabadi Pour; Hamta Ranjbar; Abolfazl Davari Nejad; Mahdi Noureddini; Behrang Alani
Journal:  Cancer Gene Ther       Date:  2022-01-26       Impact factor: 5.854

5.  Let-7i-5p functions as a putative osteogenic differentiation promoter by targeting CKIP-1.

Authors:  Yang Zhang; Wei Cheng; Biao Han; Yong Guo; Shuping Wei; Lu Yu; Xizheng Zhang
Journal:  Cytotechnology       Date:  2021-01-04       Impact factor: 2.058

6.  Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.

Authors:  Duanfeng Jiang; Xin Wu; Xiaoying Sun; Wei Tan; Xin Dai; Youbang Xie; Ashuai Du; Qiangqiang Zhao
Journal:  J Nanobiotechnology       Date:  2022-01-10       Impact factor: 10.435

7.  LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis.

Authors:  Yan Xie; Li Rong; Min He; Yuyou Jiang; Haiyu Li; Li Mai; Fangzhou Song
Journal:  Aging (Albany NY)       Date:  2021-12-13       Impact factor: 5.682

Review 8.  Exosomal RNAs: Novel Potential Biomarkers for Diseases-A Review.

Authors:  Jian Wang; Bing-Lin Yue; Yong-Zhen Huang; Xian-Yong Lan; Wu-Jun Liu; Hong Chen
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

9.  Human umbilical cord-mesenchymal stem cells-derived exosomes carrying microRNA-15a-5p possess therapeutic effects on Wilms tumor via regulating septin 2.

Authors:  He Huang; Peilin Zhong; Jianxing Zhang; Xinghe Chen; Jinwen Chen; Tian Lin; Qiang Wu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 10.  Roles of Mesenchymal Stem Cell-Derived Exosomes in Cancer Development and Targeted Therapy.

Authors:  Zixuan Sun; Jiaxin Zhang; Jiali Li; Mi Li; Jing Ge; Peipei Wu; Benshuai You; Hui Qian
Journal:  Stem Cells Int       Date:  2021-07-10       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.